Skip to content
naulon
Not checkedNot checked for notices yet.

Taiwan consensus statement on the management of chronic hepatitis B

Rong-Nan Chien, Jia-Horng Kao, Cheng-Yuan Peng and 12 more

Journal of the Formosan Medical Association · 2019

doi:10.1016/j.jfma.2018.11.008 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The experts of Taiwan Association for the Study of Liver (TASL) have actively participated and led the guidelines on hepatitis B virus (HBV) management by Asian Pacific Association for the Study of Liver (APASL) which is the first international association for the study of liver to publish the statement on HBV management before. However, there are more and more new data on the natural history and treatment of HBV infection in the past decade. These include new application of an old biomarker (quantitative HBsAg), clinical significance of HBV genotype and naturally occurring mutations, the role of non-invasive examination in evaluating severity of hepatic fibrosis, clinical significance of outcome calculators, new drug or new combination strategies towards more effective therapy and organ transplantation including liver and non-liver transplantation. It is time to publish the guidelines on HBV management of Taiwan. Hence, TASL have conducted an expert meeting to review, to discuss and to debate the relevant literatures, followed by draft the manuscript of HBV management guidelines and recommendations. The guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patient receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included. Keywords: Chronic hepatitis B, Pegylated interferon alfa, Entecavir, Tenofovir disoproxil fumarate, Tenofovir alafenamide

Abstract licence: CC BY-NC-ND

References312

    40 more references, whose wording the paper’s licence keeps private.

    All 312 references

    Cited by papers we hold1

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.